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Abstract
Reverse phase protein arrays (RPPA) are an efficient, high-throughput, cost-effective method for the quantification of
specific proteins in complex biological samples. The quality of RPPA data may be affected by various sources of error. One of
these, spatial variation, is caused by uneven exposure of different parts of an RPPA slide to the reagents used in protein
detection. We present a method for the determination and correction of systematic spatial variation in RPPA slides using
positive control spots printed on each slide. The method uses a simple bi-linear interpolation technique to obtain a surface
representing the spatial variation occurring across the dimensions of a slide. This surface is used to calculate correction
factors that can normalize the relative protein concentrations of the samples on each slide. The adoption of the method
results in increased agreement between technical and biological replicates of various tumor and cell-line derived samples.
Further, in data from a study of the melanoma cell-line SKMEL-133, several slides that had previously been rejected because
they had a coefficient of variation (CV) greater than 15%, are rescued by reduction of CV below this threshold in each case.
The method is implemented in the R statistical programing language. It is compatible with MicroVigene and SuperCurve,
packages commonly used in RPPA data analysis. The method is made available, along with suggestions for implementation,
at http://bitbucket.org/rppa_preprocess/rppa_preprocess/src.
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Introduction
In the last decade, the study of cancer biology has been
accelerated by many technological advances, enabling analyses of
the genome at both high resolution and throughput. This has led
to the identification of mutations and biomarkers specific to
various cancer types and patient sub-groups. However, clinical
trials of targeted therapy guided by these studies have met with less
success [1,2]. One of the reasons for this is that while the causes of
cancer are genetic, they result in cellular malfunction at the level of
proteins. While changes in each level may be observed discretely,
they are related intimately through processes such as translation of
mRNA to protein and the control of gene transcription by
proteins. Further, proteins can interact with metabolites post-
translationally. This increases the complexity of the proteome via
the existence of multiple forms of – e.g. phosphorylated,
nitrosylated and methylated – molecules that vary in function.
There is hence a need for reliable and affordable methods for
protein measurement, at a scale capable of complementing today’s
genomics studies, so that together, they may reveal the mecha-
nisms driving cancer.
Reverse phase protein array (RPPA) technology is a powerful
technique for measuring the activities of proteins from tissue- and
cell-derived lysate. It is an inexpensive, high throughput,
quantitative method with low sample requirements, making it
ideal for large-scale proteomic profiling studies. In RPPA, small
(,ml) amounts of lysate extracted from biological samples under
study are evenly spotted onto the surface of glass slides coated with
an absorbent material such as nitrocellulose. A single RPPA slide
of 2 cm65 cm can be used to simultaneously measure the levels of
a protein in thousands of samples at a time, using an automated
and efficient procedure that can be scaled up to hundreds of
proteins [3–5]. Each slide is probed with a primary antibody
against the protein of interest, sensitive to pg-ng of protein [6],
followed by a secondary antibody. A colorimetric or fluorescent
signal is then generated, in proportion with the secondary
antibody bound, and may be quantified to yield estimates of
relative protein concentration in each sample.
RPPA design has several advantages over existing methods for
protein detection. Unlike methods such as Western Blotting and
2D-Gel Electrophoresis, RPPA has high throughput and low
sample requirements. While other assays such as multiplexed flow-
cytometry and microsphere-based assays retain some of these
advantages, they are far more expensive than RPPA and are often
more labor intensive [7]. Mass spectroscopy (MS), which is
another method used in large-scale protein level studies, can
analyze the proteins in a sample using both unbiased and targeted
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approaches. However, current methods for MS require high
sample volumes and the time required for sample analysis can be
high. Reverse Phase Protein Arrays have enabled studies of
protein networks implicated in different cancers [8,9], infectious
disease [10] and the responses of cells to various drugs [11–13].
However, many of the factors that make RPPA an appropriate
choice for proteomics studies also introduce noise into the data.
For example, the use of targeted antibodies enables the
measurement of low-abundance proteins, but low antibody
specificity can lead to promiscuous binding and false positives
[14,15]. Similarly, the handling of low sample volumes can lower
the signal to noise ratio of the results [16]. The reliability and
reproducibility of RPPA data are a key determinant of the utility of
such studies. We examine one factor that contributes to noise in
the RPPA data – spatial heterogeneity – and describe a method for
correcting it, thereby enhancing the quality of the data.
Spatial variation in RPPA slides occurs due to unequal exposure
of the slides to the experimental reagents used. This causes non-
uniform signal generation, resulting in systematic variations across
the area of each slide. Spatial heterogeneity is obvious when
identical samples distributed over a slide produce variable signal
intensities. Consequently, variance across identical samples serves
as a reference with which one can measure and then correct errors
arising from this heterogeneity (Fig. 1). We show that spatial
differences affect the results of RPPA data obtained from diverse
biological datasets. We use a simple, flexible and powerful 2D
interpolation method to normalize the data, resulting in signifi-
cantly enhanced data quality as measured by improvements in
reproducibility and the signal to noise ratio of the results. Also,
data from antibodies that were previously unusable are rescued
with the method, improving the utility of the studies performed. R
code for the method is provided as a package that can be used in
conjunction with MicroVigene, currently a widely used platform
for the analysis of RPPA data.
Materials and Methods
Data sets analyzed using normalization routine
RPPA data for this study were obtained from slides printed with
various human cell-line and tumor derived samples and probed
with antibodies specific to proteins relevant to the study. The
details of the method are provided in the results. We tested this
method on the following data sets.
1) Set A - Quality control samples. This dataset was
comprised of 16 slides, each identically printed with sample and
then queried with a single primary antibody. The samples in these
slides were obtained from a quality control study performed in the
M.D. Anderson Cancer Center RPPA core-facility and a list of the
antibodies used is provided in table S2.
2) Set B -Humanmelanoma cell line-derived samples. This
data set was obtained from experiments performed in-house in the
Sloan Kettering Institute. The melanoma cell line SKMEL-133, a
V600EBRAF/PTEN null mutant cell line kindly gifted to us by Dr.
David Solit, MSKCC [17], was perturbed with 10 small molecule
inhibitors (table S1) targeting specific kinases that control cell death
and proliferation. Cells were treated with each drug individually as
well as with all pairwise combinations of the drugs. Three biological
replicates of each experimental condition were generated, consti-
tuting approximately 300 samples that were measured with RPPA.
Cell lysate from each sample was spotted onto slides and probed
using 159 antibodies (table S2) to measure the quantities of clinically
relevant proteins or phospho-proteins in those samples. Several of
the slides were probed with the same antibody 2–3 times, resulting
in a total of 238 slides and 53 antibodies with replicate slides.
3) Set C – Miscellaneous anonymized samples. A data set
comprised of 30 slides from cell-line data processed at the M.D.
Anderson Cancer Center.
Preparation, layout, printing and quantification of lysate
array samples
Homogenized cell pellets consisting of cellular proteins are
derived from cells grown in-vitro or from tissue samples in-vivo.
Samples are lysed and the protein extract obtained is diluted based
on the design of each experiment. In the slides comprising the data
sets in this study, each sample undergoes a K serial dilution four
times, leading to a total of 5 concentrations per sample. These
initial serial dilutions are performed manually. Diluted samples are
then robotically spotted onto the surface of slides coated with
nitrocellulose. In our experimental design, each sample and
positive control is printed in five dilutions. The slides are laid out
as grids of 132644 spots, comprised of 48 subgrids containing 121
spots each. Thus, each subgrid accommodates 22 samples and 2
positive control samples, in 5 dilutions each. A subgrid is also
printed with a single buffer spot that serves as a negative or
background control. Each slide thus accommodates 1056 serially
diluted samples and 96 positive control samples (with 5 dilutions
per sample), and an additional 48 negative control spots (Fig. 2).
The positive control spots, are printed at fixed intervals across the
length and breadth of each slide, and are technical replicates of
each other, obtained from a single batch of standard mixed cell
lysate [18]. Since the controls are designed to contain sufficient
amount of each of the proteins in the antibody panel for reliable
detection, similar levels of the concerned protein should also be
detected in experimental samples when the appropriate dilution of
antibody is used. The negative control spots consist of buffer
containing no protein and are hence informative of the level of
background signal generated.
Protein in each sample is quantified by washing the slide with a
solution of primary antibody followed by secondary antibody. The
biotinylated secondary antibody interacts with a streptavidin
bound peroxidase to catalyze the deposition of a biotinylated
brown tyramide compound on the surface of the spot. The
intensity of the colored signal thus generated is proportional to the
amount of secondary antibody and protein bound to the slide.
Signal intensities obtained by scanning images of the slides were
quantified by MicroVigene software [19]. These are then
translated into relative protein concentrations using an R package
called SuperCurve [20]. SuperCurve estimates the concentrations
of all the samples on a slide with respect to one another. The
estimation is based on the assumption that all the samples on a
slide lie on a single dose response curve, since the hybridization
kinetics of all samples have similar chemistry. The curve thus
obtained may be used to obtain the relative concentration of each
sample on the slide.
Assessment of data quality
The effectiveness of normalization was assessed based on the
behavior of biological and technical replicates compared before
and after normalization. Successful normalization should reduce
noise, resulting in improved comparability of data and should
bring replicates closer to each other. We define technical
replicates as spots that are printed from lysate that was obtained
from a single batch of cells in a single experiment. When printed
onto a single slide, they are called intraslide replicates and when
printed onto different slides, they are interslide replicates. For
example, all the positive control spots belonging to a single dilution
on a single slide are intraslide technical replicates because they
were obtained from a single mix of cells and subjected to dilution
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in a batch before the lysate was printed onto slides. Biological
replicates are spots that are printed from cell lysate obtained
from cells that were subjected to the same experimental
conditions, but in separate batches. For example, in procuring
dataset B, SKMEL-133 cells were grown in 3 different petri-
dishes, and each was subjected to normal medium spiked with a
dose of EGF ligand. They were then used to yield three separate
cell pellets that when lysed and printed onto a slide, gave rise to
biological replicate spots.
We expect technical and biological replicates to have different
degrees of variability. Similarity of technical replicates is indicative
of the reliability and uniformity of steps in the procedure such as
printing, probing and scanning. On the other hand, biological
replicates may vary for a number of reasons. The heterogeneity
inherent to populations of cells obtained from both cell lines and
tumors may make subsets of such populations behave differently
when subjected to the same treatment. Several other factors could
introduce biological variation, such as time to freezing and the
presence of stromal and endothelial cells in tumor-derived
samples, or the sample preparation method used [21–24]. Thus
when technical variability is low, the differences between biological
replicates can yield useful information about cellular variability in
the samples studied.
To determine how spatial normalization improves the quality of
RPPA data, we calculated
1. Agreement between interslide and intraslide technical repli-
cates across 16 pairs of duplicate slides from dataset A, and 53
pairs of duplicate slides from dataset B.
2. Agreement between intra-slide biological replicates in a 238-
slide melanoma cell line study.
Figure 1. Steps in the acquisition and processing of RPPA data. Cells derived from different in vitro and in vivo systems are lysed and protein
extracted (1). Serially diluted extracts are printed onto the surface of slides (2) where primary and secondary antibodies bind to the protein of interest
and generate a signal proportionate to the amount of protein in each sample. Each slide can accommodate 5808 printed spots, for different numbers
of total samples depending on the layout and number of dilutions used (3). Readouts obtained are translated to sample intensities after scanning and
processing of the slides (4). Intensities of positive control spots (horizontal yellow spots in (4)), which are technical replicates of each other, may be
used to evaluate and correct spatial variation observed in each slide. Spatial correction of data can improve data quality resulting in better estimates
of relative protein concentration and improved agreement between inter- and intra-slide replicates from various experiments.
doi:10.1371/journal.pone.0097213.g001
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Agreement was evaluated with the Pearson’s correlation (r)
between corresponding spot intensities (IA and IB) across duplicate
slides and the coefficient of variation (%CV) between replicates
within-slide, where m denotes the mean and s the standard
deviation of the spot intensities (I) or protein concentrations (P)
measured.
rIA,IB
~
cov(IA,IB)
sIAsIB
~
E½(IA{mIA )(IB{mIB )
sIAsIB
ð1Þ
%CV~
sP|100
mP
ð2Þ
Results
Bilinear interpolation of correction factors to remove
spatial biases in RPPA data
The central assumption is that in the absence of spatial variance
all positive controls of a given dilution should yield equal
intensities. Consequently, observed variability of positive control
intensities is a survey of the spatial bias on the slide. With this
information, we can systematically factor out the spatial bias at any
location based on neighboring positive control intensities.
We define the relationship between the measured sample
intensity I(x,y) and the true intensity I9(x,y) in terms of a correction
factor CF(x,y) that represents spatial variance.
I 0(x,y)~
I(x,y)
CF (x,y)
Correction factors are simply the ratio of positive control
intensities PCI(x,y) to some reference intensity ,PCI..
CF (x,y)~
PCI(x,y)
SPCIT
Here, we choose the mean positive control intensity ,PCI. to
be the reference intensity. CF values above 1 indicate regions on
the slide where there is a bias towards larger intensities. CF values
Figure 2. In the experimental design we use for the analysis of the samples in sets A and B, lysate is spotted in 96 arrays consisting
of 22 samples, two positive controls and one buffer spot each. Each of the samples and the positive controls is printed in five 1:2 serial
dilutions each.
doi:10.1371/journal.pone.0097213.g002
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below 1 indicate regions on the slide where there is a spatial bias
towards smaller intensities.
However, these correction factors are not directly calculable at
sample locations precisely because those locations do not contain
positive controls. To compensate for this missing information, we
use interpolation to approximate pseudo-positive control intensities
at the sample locations.
Interpolation is the calculation to approximate the value of a
function f(x,y) at specific locations (x,y) given fixed knots or
measured function values at neighboring locations f(xc, yc) and is
analogous to ‘‘Connect the Dots’’. Linear interpolation means we
connect the dots with lines. The points lying on the lines between
the dots are the interpolated values, and the dots themselves are
fixed knots or anchor points. The interpolated values are
approximations inferred based on nearest neighbor data. In this
case, we will use the measured positive control intensities to
interpolate or approximate pseudo-positive control intensities at all
locations on the slide.
Consider a location (x,y) that lies between four measured
positive control spots with corresponding intensities PCI(xa,ya),
PCI(xa,yb), PCI(xb,ya), PC(xb,yb).
PCI(x,ya)~
xb{x
xb{xa
PCI(xa,ya)z
x{xa
xb{xa
PCI(xb,ya)
PCI(x,yb)~
xb{x
xb{xa
PCI(xa,yb)z
x{xa
xb{xa
PCI(xb,yb)
PCI(x,y)~
yb{y
yb{ya
PCI(x,ya)z
y{ya
yb{ya
PCI(x,yb)
These are pseudo-positive control intensities (indicated by an
asterisk) in that they are approximations for what a control
intensity at that location would have been had it been spotted with
control sample. The correction factors at these locations are
calculable with simple division by the reference positive control
intensity.
CF(x,y)~
PCI(x,y)
SPCIT
The bilinear interpolation calculation described above reflects
only our assumptions about the smoothness of the spatial bias
between measured positive control locations. It says nothing about
the relationship any sample intensity has to another sample
intensity. A similar correction can be applied after performing a
cubic spline interpolation between the correction factors. Overall,
the results of normalization using spline interpolation are similar to
those with bilinear interpolation (table S3). Hence we use the
simpler of the two, bilinear interpolation, for normalization (Figure
S1). Further, in the sample and control format used in our
experiments, there are 96 sets of positive controls printed in 5
dilutions each. We use the median of each set as anchors for our
interpolation step as this dilution is the most likely to be in the
linear range of the assay for the set of antibodies used in the
experiment. Users of the method are encouraged to design their
experiments such that all the query samples are contained within
the interpolation region of the positive controls. In our design, a
portion of the slide (1/12th) does not have positive controls at its
periphery and hence, each sample in this region was normalized
by the closest correction factor evaluated.
Spatial normalization improves Coefficient of Variation
between biological replicates
Spatial normalization improves agreement between intraslide
biological replicates in dataset B and ‘rescues’ previously discarded
slides enabling further analysis of these proteins. Melanoma cell
line samples were acquired for a large study aimed at
understanding the basis of RAF inhibitor resistance in certain
melanoma cell lines. Cell lysate was obtained from a melanoma
cell line SKMEL-133 and subjected to various drug treatment
conditions in triplicate, resulting in approximately 300 samples
that were then quantified using RPPA. Agreement between the
biological replicates was calculated before and after normalization.
Around 10% of the slides (25/238) show increases of over 5% in
agreement between biological replicates after normalization
whereas only 1.2% (3/238) slides show a worsening of CV by
over 5% with normalization. Despite increased agreement overall,
biological replicates show different degrees of improvement with
spatial normalization (Fig. 3).
The data from this study were used to train a mathematical
model of melanoma biology in SKMEL-133. To maximize model
accuracy, only data points with sufficient reliability were kept for
model incorporation and training. Slides were selected if the
average coefficient of variation (%CV) of biological replicates
within each slide was seen to be less than or equal to 15%. This
threshold was arbitrarily selected by the authors and is left to the
discretion of the user. %CV, which is the ratio of the standard
deviation between observations to the mean of those observations,
expressed as a percentage, is a good measure of signal to noise in
biological data and rises with noise in the data. A set of 168 slides
was originally selected after discarding saturated and defective
slides. Of the 168, when we evaluated %CV across all biological
replicates in each slide, 15 slides were unusable because of %CV
greater than 15%. After normalization, only 7 slides had %CV
greater than 15%. The slides that were rescued by spatial
normalization measured AKT, PARP, BCL2, BIM, ATR, YAP,
IGFBP and FAK (Fig. 4). In certain cases, %CV appears to rise
after normalization. This could reflect real noise present in the
data. However, the cases where this occurs are those where %CV
is significantly below the cutoff of 15% and hence this did not
affect the selection of antibodies in our study. To further verify this
result, we also calculated the Z9-factor [25] of each slide before
and after spatial normalization. In agreement with the %CV
improvements we observed in biological replicates, the per-slide
Z9-factor evaluated in dataset B also improves in .98% of the
slides used in the experiment (details and calculations provided in
Fig. S3).
Spatial normalization modestly improves the agreement
between inter-slide replicates
To evaluate whether spatial normalization improved data
quality significantly, we compared the agreement between
technical and biological replicates before and after normalization.
We compared the Pearson’s correlation of the estimated concen-
trations of samples printed at equivalent locations across 69 pairs
of duplicate slides procured independently from sets A and B to
assess interslide reproducibility. Here, duplicate slides are slides
that were printed with the same samples in equivalent locations on
each slide.
Many slide pairs improve in overall correlation between
concentrations, with only a minority of the slide pairs showing a
Spatial Normalization of RPPA Data
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large such improvement. Further, slides showing a modest
improvement in the behavior of interslide technical replicates
with normalization often show greater improvements in concor-
dance of biological replicates (Fig. 5 and table S4). Earlier studies
using RPPA have consistently shown that such correlations
evaluated between the concentrations of interslide replicates are
generally high [18] but may not be the best measure of
improvement in data quality after normalization.
Spatial normalization improves Intra-slide reproducibility
of technical replicates
The slides evaluated for interslide reproducibility each have 480
positive controls, spotted as 96 sets of 5 dilutions each. The 96
points within a dilution are hence all technical replicates of one
another. While the normalization method uses one of these sets,
the median set, as anchor points for evaluating spatial variation
and correction factors, we can use the remaining dilutions of the
positive controls to measure %CV between each set before and
after normalization. Doing this showed significant improvements
in agreement between each such set of technical replicates, across
most antibodies used. (Fig. 6) In the melanoma data-set, agree-
ment between technical replicates showed an average improve-
ment of 4%, with %CV falling from 12% to 8%, after
normalization across slides probed with different antibodies.
Further, 16 out of the 168 antibodies showed improvements of
10% or above in the coefficient of variation between technical
replicates.
Discussion
RPPA is one of two main techniques used in large-scale
proteomics studies today – array based techniques and mass
spectrometry. High-throughput, low sample requirement and high
sensitivity make it a promising technology with which to examine
protein networks in a variety of systems including cell lines and
tissue samples. However, some of the features that make RPPA an
Figure 3. Coefficient of variation (%CV) of biological replicates across all antibodies before and after normalization clearly improve
with normalization. The degree of improvement varies from antibody to antibody (higher for EGFR-pY992 and cJUN-pS73 than YB1-pS102) and is
significant for many antibodies relevant to signaling in the melanoma cell lines studied.
doi:10.1371/journal.pone.0097213.g003
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Figure 4. Spatial normalization reduces variance between biological replicates in the majority of the slides comprising a melanoma
cell line study. In the study, a cutoff coefficient of variation (CV) of 15% is used to decide whether slides are retained for biological analysis. After
spatial normalization, CVs in 8 slides (Caspase 9, IGFBP2, ATR, COX2, FAK_pY397, BCL2(mouse), PARP, AKT) that were previously unusable drop to
acceptable values. One slide - PCNA(mouse) - that had earlier been used in analysis is rejected after normalization.
doi:10.1371/journal.pone.0097213.g004
Spatial Normalization of RPPA Data
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appropriate choice for several kinds of proteomics studies, such as
antibody-based detection, where antibodies have may different
target-affinities and variable specificities, also add noise to the data
it generates. Hence noise reduction and data normalization are
essential for the successful application of RPPA. Our normaliza-
tion technique evaluates one source of noise in RPPA data –
spatial variation – and uses the measured variation to correct the
data leading to increased reproducibility between duplicates in
various studies. The method also makes the data from previously
discarded, noisy slides usable in analysis, potentially expanding the
scope of the biological questions that a set of RPPA experiments
may address.
Among the genomics platforms, such as DNA microarrays,
standards for experimental design and analysis have greatly
improved the quality of those data and the scope of the studies
that they enable [26–29]. This has lead to collaborative efforts
such as the TCGA that have significantly enhanced our
understanding of various cancers [30]. Among the protein activity
measurement platforms, there are fewer methods that similarly
address data quality. One such method [31], in which control
samples are used to normalize for spatial and scaling errors in
RPPA data successfully reduces intra-array replicate CV by up to
70%. However these improvements were the result of printing of
as many control samples as each slide contained query samples
and is hence expensive. Further, the published method was only
applicable to a specified sample layout. Our method corrects a
significant and systematic source of bias in RPPA data effectively
reducing error in sample sets normalized with relatively few
controls. Among the melanoma data we corrected, for instance,
fewer than 2% of the samples were used to normalize a total of
5808 samples. Further, the method is flexible, allowing the user to
correct for spatial biases in a variety of formats containing identical
control samples that contain a level of the protein of interest that is
within the linear detection range of the assay used. Others in the
research community have similar goals and improved standard-
ization of analysis methods will help realize the potential of RPPA
in, e.g., characterizing the signaling response to drug treatment or
in training mathematical models of biological systems.
As this manuscript was completed, two other alternative
methods for spatial normalization of RPPA data were published
[32,33]. The first, by Troncale et al., uses a non-parametric model
that takes into account every sample’s Row and Column location
while fitting the obtained intensities to relative protein expressions,
thus adjusting for spatial effects along with other sources of
variation addressed by the paper, such as background and total
protein deposited at each spot. The method of Neeley et al. is
similar in ideology to ours, in that it uses the variation observed
between identical controls printed at various locations on each
Figure 5. Correlation between concentrations of samples printed across duplicate slides increases slightly with normalization
(upper panels, LRR, melanoma samples and probed with anti-pMAPK antibody). Coefficient of variation between the concentrations of
biological replicates printed on one of these slides improves after normalization (lower panels, LRR).
doi:10.1371/journal.pone.0097213.g005
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array to normalize for spatial effects. The correction is model
based, and is specific to an array format that is commonly used in
the community. While a systematic comparison of existing
methods would help a user to select the method best suited to
their experiment and data, this is beyond the scope of our current
work. We compare the changes in reproducibility of data observed
using our method with Neeley et al. across the antibodies in the
melanoma dataset. These results are provided in (Figure S2). More
extensive comparisons of the existing methods may aid in the
selection of a set of standard methods for data normalization, or an
improved understanding of what quantification and normalization
methods work the best for different types of experiments. This
would be beneficial to the RPPA community, where comparisons
Figure 6. Coefficient of variation between intensities of intraslide technical replicates in dataset B decreases significantly with
normalization. One out of 5 dilutions of positive controls is used for spatial normalization. The correlation of the remaining positive controls, which
are technical replicates within each dilution, is observed after normalization. Correlations increase with normalization for each of the observed
dilutions.
doi:10.1371/journal.pone.0097213.g006
Spatial Normalization of RPPA Data
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of experimental results are currently confounded by a lack of
standardization.
A metric frequently used to assess data quality in RPPA is
interslide and intraslide correlation between spot intensities of
technical replicate spots [18]. While this gives us some confidence
about the reliability of the results, it may not be an adequate
measure of reproducibility. Since RPPA has a low dynamic range
as compared to some other proteomics methods, this range is often
expanded by printing multiple dilutions of each sample on the
surface of a single slide. The dilutions of a sample may be widely
separated in intensity, and correlations measured across all spot
intensities on a slide may be biased by the range of intensities
spanned by each slide (Fig. 7). When evaluating interslide
correlations, we attempt to reduce this bias by comparing relative
protein concentrations rather than intensities. Nonetheless, mea-
sures of intraslide technical and biological replicate equality can be
more informative of data quality than Pearson’s correlation. Other
metrics of data quality, such as the Z9factor [25] and a Welch’s t-
statistic [34] to evaluate the mean difference between the positive
and negative controls before and after normalization also showed
Figure 7. Correlation calculations performed using intensities of all spots printed onto duplicate slides may be a misleading
measure of reproducibility because of experimental design that uses multiple dilutions to evaluate sample concentrations. In the
case of two identical slides probed with anti-pBAD antibody, overall correlation coefficient R = 0.82 whereas correlations of the individual dilutions are
lower.
doi:10.1371/journal.pone.0097213.g007
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improvements from normalization for the vast majority of samples.
(figures S3 and S4).
The spatial normalization technique we implemented not only
significantly decreased coefficient of variation improved agreement
between biological and technical replicates within slides, but also
made it possible to analyze the data from many slides that were
previously unusable because of high variation. A particular
example is our use of the antibody for PARP-1 in a study of
melanoma samples subjected to various treatment conditions,
where the %CV between biological replicates decreased from 21%
to 13%, enabling more reliable use in the study after normaliza-
tion. Poly (ADP ribose) polymerase (PARP) proteins (PARP-1 and
PARP-2) play a critical role in controlling necrosis and apoptotic
cell death. These PARP proteins are located inside the nucleus and
take part in DNA-repair in response to DNA breaks and facilitate
transcription, replication and DNA base excision repair [35].
PARP inhibitors (Olaporib, iniparib and veliparib) are undergoing
clinical trials in BRCA mutated ovarian and breast cancer patients
[36]. Furthermore, PARP-1 has been linked to altered control of
p53-mediated DNA response and NFKappa-B response [37].
Consequently, accurate quantification of cleaved PARP-1 could be
critical in understanding the complex signaling mechanisms
involving PARP-inhibition as well as perturbations involving
BRCA1 and BRCA2.
Other proteins similarly rescued in this and other studies could
expand the scope of the biological problems addressed by RPPA.
One context in which spatial normalization could be very relevant
is in the analysis of tumor samples using RPPA, that due to
requirements of throughput, cost and limited availability of patient
material, are often unable to have sample replicates within slides.
One such effort, belonging to the umbrella of TCGA projects,
measures and compares protein abundance data across various
tumors. In cases such as this, spatial variation alone could cause
the appearance of differences that may bias the results. Hence it is
very important that these data be appropriately normalized before
use and analysis in other projects R code for our spatial
normalization method can be used in conjunction with Micro-
Vigene and SuperCurve. It is flexible and may be adapted to
several different kinds of experimental designs, with the user
specifying the locations of positive controls or other identical
samples to be used as reference points for normalization.
Our method is one of several early efforts for the standardiza-
tion and quality control of RPPA data. As data acquisition
methods improve and RPPA moves into more widespread use, we
advocate the adoption of common standards for the evaluation
and correction, where possible, of systematic errors in RPPA data
as well as in the analysis of these data to enable larger, multi-center
studies and improve comparability across individual studies.
Supporting Information
Figure S1 Coefficient of variation between all biological
replicates, and across 237 antibody slides used in a
melanoma study, before and after normalization of
sample intensities using bilinear interpolation and cubic
spline. Both methods result in greater agreement between
replicates due to normalization.
(TIFF)
Figure S2 Coefficient of variation between biological
replicates in the melanoma study (SET B) appears to
worsen for many antibodies when normalization is
implemented using the method of Neeley et al.
(TIFF)
Figure S3 Spatial normalization improves the quality of
the data from almost all the antibodies in a set of slides
(Set B) printed with lysate from the melanoma cell line
SKMEL-133. 30% of the slides which had a Z9-Factor of
lower than 0.5 show Z9.0.5 after normalization. Further,
unusable data from nearly 11% of the slides (26/238) show a Z9.
0.25 after normalization.
(TIFF)
Figure S4 Spatial normalization increases the observed
differences between the positive and negative controls in
a set of slides (Set B). 229 out of 238 slides (96%) of this set
show a clearer separation between the controls after normaliza-
tion.
(TIFF)
Table S1 A list of the drugs used to perturb a melanoma
cell line and the doses used, both singly and in all
pairwise combinations.
(XLSX)
Table S2 All slides in the melanoma study with
antibodies and dilution used in each.
(XLSX)
Table S3 Contains results of a comparison of duplicate
slides obtained form studies conducted in SKI and MDA.
Results of this analysis are reported as interslide and intraslide
replicate CVs in the results section of the paper.
(XLSX)
Table S4 Compares the % CV between the concentra-
tions of biological replicates printed from a melanoma
cell line study. CVs reported correspond to that before
normalization, and to that after normalization with two methods
– bilinear interpolation and cubic spline interpolation.
(XLSX)
Code S1 Contains the R code for the method along with
example data and guidelines for use.
(ZIP)
File S1 Contains details of supplementary performance
assessment of the method.
(DOCX)
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